CMTR2

Overview

CMTR2 (Cap Methyltransferase 2; also known as FTSJD1) encodes an mRNA cap 2’-O-methyltransferase responsible for methylating the ribose of the second nucleotide adjacent to the 5’ cap. It was identified as a novel significantly mutated gene (SMG) in lung adenocarcinoma in the TCGA Pan-Lung analysis, enriched for frameshift mutations, suggesting a tumor suppressor role in lung cancer.

Alterations observed in the corpus

  • CMTR2 (also known as FTSJD1) was identified as a novel SMG in lung ADC enriched for frameshifts; also recurrent in SF3B1 and SNRPD3 context in the TCGA Pan-Lung analysis PMID:27158780.

Cancer types (linked)

  • LUAD: CMTR2 is a novel significantly mutated gene in lung adenocarcinoma, enriched for frameshift mutations suggesting loss-of-function role PMID:27158780.

Co-occurrence and mutual exclusivity

  • Recurrent alterations observed alongside SF3B1 and SNRPD3 in the same TCGA lung cancer analysis; precise co-occurrence statistics not reported PMID:27158780.

Therapeutic relevance

  • CMTR2’s role as a frameshift-enriched SMG in lung ADC suggests a candidate tumor suppressor; no direct therapeutic targeting has been reported in this corpus.

Open questions

  • Functional characterization of CMTR2 as a cancer driver in lung ADC is lacking; frameshift enrichment suggests TSG role but requires experimental validation PMID:27158780.

Sources

This page was processed by crosslinker on 2026-05-14.